Mednet Logo
CommunityRadiation Oncology

Would you offer hypofractionation to a patient in the salvage/adjuvant post-prostatectomy setting outside of a clinical trial?

Given GU003 presented at ASTRO 2021- how does this impact your recommendations for adjuvant and salvage prostate RT?
4 Answers
Mednet Member
Mednet Member
Radiation Oncology · Duke University School of Medicine
Answered on · Updated on

No unless operating in a resource-scarce environment. My colleagues and I have been using 2.5 Gy for almost a decade at the Durham VA. The results have been recently published.NRG trial (GU003-Mark Buyyounouski PI) comparing 66.6/1.8 Gy to 62.5/2.5 Gy has been accruing very quickly and will close ve...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Virginia Commonwealth University Medical Center
Answered on

I agree with Drs. @Dr. First Last, @Dr. First Last and @Dr. First Last. The reported follow-up from GU003 as presented at ASTRO just isn't long enough to be confident that we won't see an increase in late effects in the hypofractionation arm in this trial in the future. As my mentors were fond of sa...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Fox Chase Cancer Center
Answered on

At Fox Chase, we do not offer hypofractionated IMRT for adjuvant and salvage post-prostatectomy patients except on a clinical trial (NRG GU003). We have been treating men with intact prostates for more than 15 years with hypofractionated IMRT, but we are awaiting the results from this clinical trial...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Mayo Clinic
Answered on · Updated on

This is a very good question. In my opinion, this should only be done in a study. At Mayo Clinic, we have opened a 5-fraction post-prostatectomy study.

Join for free or sign in to see the full answer